British Journal of Dermatology · 2008 · 18 citations · 33 references
Life SciencesImmunologyPathobiologyAutoimmunityCellular ImmunologyImmunoregulationCell-mediated ImmunityChronic RejectionGraft-versus-host DiseaseRegulatory T CellsT Cell BiologyTransplant RejectionCd4 Positive T CellsGraft Versus Host Disease ModulationGraft-versus-host Disease PathophysiologyPeripheral Regulatory T CellsSuppressionTransforming Growth Factor Beta RegulationTransforming Growth Factor Beta Signaling In T Cell DifferentiationTransforming Growth Factor Beta-mediated Immune Suppression
BACKGROUND: The suppressive mechanism of CD4+CD25+ regulatory T cells (Tregs) is poorly understood. It is also not known how to obtain enough peripheral Tregs, and how to make them effective in ameliorating a murine lupus-like syndrome of chronic graft-versus-host disease (cGVHD). OBJECTIVES: To confirm the contribution of transforming growth factor (TGF)-beta1 in the function of CD4+CD25+ Tregs in vitro, and to identify in vivo suppressive effects of different Tregs generated through TGF-beta1. METHODS: Suppressive effects of freshly isolated CD4+CD25+ Tregs, TGF-beta1-expanded CD4+CD25+ Tregs (eTregs) and TGF-beta1-induced CD4+CD25+ Tregs (iTregs) in vitro were assessed. Reverse transcription-polymerase chain reaction was used to detect Foxp3. The respective roles that different Tregs might play in controlling murine lupus-like syndrome of cGVHD were analysed. RESULTS: TGF-beta1 was necessary for expanding the existing CD4+CD25+ Tregs in vitro, as well as converting peripheral CD4+CD25- T cells to CD4+CD25+ Tregs through upregulating CD25 and Foxp3. These eTregs and iTregs had a suppressive effect similar to that of freshly isolated CD4+CD25+ Tregs. The inhibitory function of iTregs could be partially blocked by anti-TGF-beta1. Importantly, it was revealed for the first time that both eTregs and iTregs had an inhibitory effect on reversing the morbidity of mice that had already developed anti-dsDNA, and iTregs gave more suppression than eTregs. Besides, iTregs could prevent the onset and slow the progress of disease in a significantly dose-dependent manner. CONCLUSIONS: Results indicate that TGF-beta1 signalling is required to maintain the suppression of CD4+CD25+ Tregs in vitro and in vivo. Together, this study suggests a possible therapeutic role for iTregs in the treatment of murine lupus-like syndrome of cGVHD.
33
Jung‐Hyun Park, Stanley Adoro, Terry I. Guinter et al. · Nature Immunology · 2010 · 5.8K citations · Full text
Shimon Sakaguchi, N Sakaguchi, M Asano et al. · The Journal of Immunology · 1995 · 5.5K citations
Life Sciences, Immunology, Pathology +17
An essential role for Scurfin in CD4+CD25+ T regulatory cells
Roli Khattri, Tom Cox, Sue-Ann Yasayko et al. · Nature Immunology · 2003 · 2.8K citations